The FDA again delayed its review of cephalosporin antibiotic ceftobiprole due to unresolved "data integrity issues," an unexpected setback for Swiss biotech Basilea Pharmaceutica Ltd. and co-development partner Johnson & Johnson Pharmaceutical Research & Development LLC. (BioWorld Today) Read More
